Strati, P., Feng, L., Westin, J. R., Nair, R., Fayad, L. E., Rodriguez, M. A., Chihara, D., Malpica, L., Henderson, J., Gallardo, M., Rivera, M., Wang, I., Bolshakova, A., Radko, A., Kurtz, D., Alig, S. K., Flowers, C. R., Alizadeh, A. A., Neelapu, S. S. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. https://doi.org/10.1038/s41467-025-62509-z